FluoretiQ develops rapid bacterial detection systems using proprietary diagnostic technology that delivers results in 15 minutes at the point-of-care. This approach addresses the critical issue of antibiotic misuse by enabling clinicians to make informed, evidence-based treatment decisions, thereby combating antimicrobial resistance.
Funding
$8.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for bacterial infection diagnostics often rely on lab-based cultures that can take up to 48 hours to produce results. This delay can lead to the misuse of antibiotics, contributing to the rise of antimicrobial resistance (AMR) and ineffective treatment. Clinicians need faster, more accurate tools to identify infections and prescribe the correct antibiotics promptly.
Solution
FluoretiQ is developing rapid diagnostic systems that deliver bacterial detection results in approximately 15 minutes at the point of care. Their proprietary NANOPLEX technology uses glycan-based probes to quickly identify and quantify bacterial species directly from patient samples. By providing rapid, lab-quality results, FluoretiQ enables clinicians to make informed decisions about antibiotic prescriptions, reducing misuse and supporting antibiotic stewardship. The company is also developing SCFI (Sub Cellular Fluctuation Imaging) technology for antibiotic susceptibility testing, further enhancing the ability to prescribe the most effective antibiotic.
Target Audience
The primary target audience includes clinicians, doctors, and healthcare providers who require rapid and accurate bacterial infection diagnostics at the point of care, as well as veterinary practices needing to diagnose urinary tract infections.
Features
- NANOPLEX technology for rapid (15-minute) bacterial identification and enumeration
- Glycan-based probes for direct bacterial detection from samples
- SCFI (Sub Cellular Fluctuation Imaging) technology for antibiotic susceptibility testing
- Point-of-care testing capability for immediate results
- Supports antibiotic stewardship by enabling informed prescribing decisions